BPC-157 and COVID-19: Evidence and Research Limits

There is no clinical evidence that BPC-157 prevents or treats COVID-19 or another infection. The article most often cited for this idea is a 2021 hypothesis paper. It connects findings from unrelated cell and animal studies to features of severe COVID-19, but it did not give BPC-157 to people with COVID-19, test the peptide against SARS-CoV-2, or measure a clinical outcome.

This guide explains what prompted the hypothesis, what the underlying studies actually tested, and what evidence would be needed before an infection claim could be evaluated in people.

Evidence at a glance

Where the COVID-19 claim came from

The 2021 paper titled BPC 157 as Potential Treatment for COVID-19 appeared in Medical Hypotheses. Its argument was that severe COVID-19 can involve endothelial dysfunction, abnormal coagulation, inflammation, and injury across several organs, while BPC-157 had produced vascular or cytoprotective findings in nonclinical models.

The paper explicitly describes its case as being based primarily on animal-model data and says appropriate drug development or human trials would be required. It is therefore a hypothesis-generating narrative, not a treatment study (Deek, 2021).

That distinction matters. A paper can assemble a plausible biological story without demonstrating that:

• BPC-157 reaches the relevant human tissue at an active concentration;
• the same mechanism occurs during SARS-CoV-2 infection;
• the compound improves symptoms, hospitalization, complications, or mortality;
• a formulation has consistent identity, purity, stability, and exposure; or
• its benefit-risk balance is acceptable.

None of those questions can be answered by analogy alone.

What the mechanism studies show

Nitric-oxide and vascular signaling

One study reported concentration-dependent relaxation in isolated rat aortic rings and signaling consistent with a Src–caveolin-1–eNOS pathway. The experiment supports a possible effect on nitric-oxide signaling in that preparation (Hsieh et al., 2020).

It does not show that BPC-157 is antiviral, prevents clotting in people with COVID-19, or improves an infectious disease outcome. Isolated rat aorta is a mechanistic model, not a human respiratory infection.

Vascular occlusion and multiorgan injury

A separate rat study used sodium laurate to produce embolization, vascular obstruction, and multiorgan injury. Outcomes were reported after BPC-157 administration (Smoday et al., 2023). This can inform hypotheses about circulation and injury responses, but the model did not involve SARS-CoV-2 or another pathogen.

Similarity between two downstream features—such as thrombosis or lung injury—does not make their causes interchangeable. A chemically induced rat embolization model cannot establish efficacy in viral disease.

Liver and other organ-injury models

Older rat experiments reported findings in liver-injury models produced by vessel ligation, restraint stress, or carbon tetrachloride (Sikiric et al., 1993). Other BPC-157 publications use trauma, toxins, ischemia, or surgical injury.

These studies ask whether a compound changes damage in a specific experimental system. They do not show that BPC-157 treats the cause of COVID-19, prevents viral replication, or produces the same balance of effects in humans.

Why indirect evidence does not establish an infection treatment

The evidence ladder contains several separate questions:

1. Mechanistic activity: Does the compound change a pathway in a cell or isolated tissue?
2. Disease-model activity: Does it change outcomes in a well-matched animal infection model?
3. Human exposure and safety: Can a characterized formulation produce predictable exposure without unacceptable harm?
4. Clinical efficacy: Does a controlled human trial improve a prespecified, meaningful outcome?

The BPC-157/COVID-19 argument begins mainly at step one and borrows from noninfectious animal models. It does not complete steps two through four. Anti-inflammatory, vascular, or tissue-protective activity can also have different consequences depending on timing, tissue, pathogen, immune state, dose, and formulation.

What human evidence exists for BPC-157?

Human evidence remains limited and is unrelated to infection treatment.

A 2025 pilot report administered intravenous BPC-157 to two adults and described short-term laboratory and vital-sign observations. Both participants had received BPC-157 before the study, there was no control group, and the study was not designed to test COVID-19 or any efficacy outcome (Lee and Burgess, 2025). Two observed participants cannot establish general safety, uncommon harms, dose-response relationships, or clinical benefit.

A 2025 systematic review of musculoskeletal literature found that 35 of 36 included studies were preclinical; the single clinical report was a small uncontrolled knee-pain series. The reviewers found no clinical safety data in the literature they searched through June 2024 (Vasireddi et al., 2025).

As of this page's review date, a ClinicalTrials.gov search for BPC-157 returns a small number of records. They concern early safety/pharmacokinetics, musculoskeletal injury, or a single-group product study—not COVID-19 or infection. A recruiting hamstring study explicitly describes BPC-157 as investigational and has no posted results (NCT07437547). A recently registered single-group gummy study also has no posted results and cannot answer an infection question (NCT07752381).

Registration shows that a study was planned or conducted. It does not prove that the intervention works, and a record with no results cannot support an efficacy claim.

FDA status and product-quality uncertainty

BPC-157 is not an FDA-approved drug. FDA states that BPC-157 is not a component of an approved human drug and has separately identified potential concerns for compounded products, including immunogenicity, peptide-related impurities, and difficulty characterizing the active ingredient. The agency says it has no or only limited safety information for proposed routes and lacks enough information to know whether administration would cause harm (FDA compounding safety review).

Approval status, evidence of efficacy, and product quality are different questions. A vendor listing, certificate, compounded preparation, or study registration does not substitute for an approved formulation supported by adequate clinical evidence.

What evidence would change the conclusion?

A credible development program would need more than another mechanism paper. Important steps would include:

• reproducible testing against the relevant virus or in a well-justified infection model;
• a chemically and biologically characterized formulation;
• pharmacokinetic and toxicology work that supports a proposed human exposure;
• prospectively registered human trials with appropriate controls and prespecified outcomes;
• enough participants and follow-up to evaluate important safety signals; and
• publication of complete results, including unfavorable and null findings.

Even positive early-stage results would not automatically establish prevention or treatment. Evidence would still need to be interpreted by population, disease stage, formulation, endpoint, and trial quality.

Frequently asked questions

Does the 2021 paper prove BPC-157 treats COVID-19?

No. It is a hypothesis paper based mainly on findings from animal and mechanistic studies. It contains no BPC-157 clinical trial in people with COVID-19.

Has BPC-157 been tested against SARS-CoV-2?

The cited BPC-157 paper discusses nitric oxide and coronavirus research, but it does not report a BPC-157 experiment against SARS-CoV-2. Evidence about one pathway cannot be assigned to a different compound without direct testing.

Do organ-protection findings in rats predict human benefit?

No. They can justify further research, but species differences, model design, exposure, timing, formulation, and disease cause can all change the result.

Is a registered BPC-157 trial evidence that it works?

No. Registration describes a protocol and study status. Efficacy requires results from an appropriate design, and results for one condition cannot simply be transferred to infection.

Is commercial availability evidence of safety or approval?

No. Availability does not establish identity, purity, FDA approval, clinical efficacy, or safety. PepGuide keeps disclosed source availability separate from editorial evidence for this reason.

Continue researching

• Review the BPC-157 profile for mechanism, safety, and regulatory context.
• Use How to Read Peptide Research to distinguish hypotheses, animal studies, and clinical trials.
• Read the PepGuide methodology for evidence and update standards.
• Check the sourcing and commercial policy before interpreting availability links.

PepGuide provides research context, not diagnosis, prescribing, or individualized treatment advice. If you have symptoms or questions about infection, contact a licensed clinician rather than substituting an investigational peptide for evaluated care.

References

1. Deek SA. BPC 157 as Potential Treatment for COVID-19. Medical Hypotheses. 2021. PubMed
2. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of the Src–Caveolin-1–endothelial nitric oxide synthase pathway. Journal of Physiology and Pharmacology. 2020. PubMed
3. Smoday IM, et al. Pentadecapeptide BPC 157 as Therapy for Inferior Caval Vein Embolization in Rats. Pharmaceuticals. 2023. PubMed
4. Sikiric P, et al. Hepatoprotective effect of BPC 157 in experimental rat liver lesions. Life Sciences. 1993. PubMed
5. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025. PubMed
6. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. PubMed
7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA
8. U.S. National Library of Medicine. BPC-157 study records. ClinicalTrials.gov